Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of NS-401 in patients with blastic plasmacytoid dendritic cell neoplasm
jRCT2031220023Phase 2Completed
- Sponsor
- Nippon Shinyaku
- Start
- Jul 2022
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tagraxofusp in Blastic plasmacytoid dendritic cell neoplasm (BPDCN), sponsored by Nippon Shinyaku. Primary endpoints: Pharmacokinetics, Dose-limiting toxicity (DLT) and 2 more. Started Jul 2022; status: completed.
02
Drugs
tagraxofusp
03
Conditions
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on jRCT2031220023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220023.